HIV drug’s Medicare costs under negotiation
The federal government is negotiating lower Medicare prices for a popular once-daily pill that treats HIV and prevents infection. The Centers for Medicare and Medicaid Services said Tuesday it seeks to lower Medicare costs for 16 medications by negotiating with their manufacturers. Among them is Biktarvy, a drug taken after HIV exposure — known as a post-exposure prophylaxis — to prevent HIV infection as well as a treatment for those living with HIV. Gilead Sciences makes it. Usage of the drug has risen significantly since it was approved by the U.S. Food and Drug Administration in 2018. More than 100,000 Medicare enrollees used Biktarvy between November […]